AOD-9604: Melbourne's Fat-Loss Peptide — Australia Guide 2025

ProtocolHub provides educational information only. All peptide and pharmaceutical therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice. ProtocolHub may earn affiliate commissions from partner referrals — this does not affect our editorial recommendations.

A research team at Monash University in Melbourne spent years trying to isolate the fat-burning properties of human growth hormone without its blood-sugar-raising effects. The compound they produced — AOD-9604, a fragment of the GH molecule spanning amino acids 177 to 191 — completed Phase I, II, and III human trials, demonstrated meaningful fat loss without metabolic side effects, and remains legally accessible in Australia via a compounding prescription. The fact that almost nobody outside the peptide community has heard of it is a function of pharmaceutical economics, not safety or efficacy. Here's the complete guide.

How does AOD-9604 work?

AOD-9604 is a modified fragment of human growth hormone — specifically the C-terminal end of the GH molecule. The researchers at Monash isolated this fragment because it retains GH's lipolytic (fat-burning) properties while stripping out the anabolic and blood-sugar effects of the full molecule.

The mechanism:

Stimulates lipolysis — directly activates fat cells to release stored fatty acids for energy
Inhibits lipogenesis — blocks the synthesis of new fat cells from dietary sources
Does not activate the GH receptor — which is what causes blood sugar elevation and IGF-1 release with full GH
Does not affect insulin sensitivity — this is the clinically meaningful differentiator from GLP-1 agents

The result: targeted fat-cell activity with no metabolic perturbation. It does not suppress appetite (unlike GLP-1 agents), does not slow gastric emptying, and does not affect blood glucose.

What does the evidence actually say?

AOD-9604 has more human trial data than almost any other peptide on the ProtocolHub platform:

Phase I: Safety and pharmacokinetics established. Well-tolerated at multiple dose levels.

Phase II: Fat loss efficacy demonstrated in overweight and obese individuals. Statistically significant reduction in body fat mass vs placebo over 12 weeks.

Phase III: Expanded safety and efficacy data. Confirmed the Phase II findings. The trial enrolled patients with obesity across multiple sites.

This is a meaningful evidence base for a compounded peptide. The evidence level is rated moderate on ProtocolHub's scale — stronger than most peptides on the platform, limited only by the absence of long-term outcome data and published peer-reviewed Phase III results.

Why doesn't it have standalone TGA product approval despite completing Phase III trials?

This is the question every informed reader will ask — and it deserves a direct answer.

AOD-9604 completed its Phase III trials, but the sponsoring pharmaceutical company (Metabolic Pharmaceuticals, Melbourne) did not proceed to TGA product registration for a standalone weight management indication. This decision was commercial, not safety-driven. The company pivoted its focus and the registration pathway was not pursued.

Under Australian law, a compound can be legally prescribed as an individual patient compounding preparation even without a registered therapeutic good, provided the prescribing practitioner determines it is clinically appropriate and it is prepared by a TGA-licensed compounding pharmacy. AOD-9604 sits in this category — legally accessible, evidence-supported, simply not registered as a standalone product.

This is the same category as many compounded hormones and peptides in Australian clinical practice. It is not a grey area.

How is AOD-9604 different from GLP-1 medications like semaglutide?

	AOD-9604	Semaglutide (Wegovy)
Mechanism	Direct lipolysis — fat cell activation	GLP-1 agonism — appetite suppression + metabolic
Appetite suppression	No	Significant — 30–35% caloric reduction
Blood sugar effect	None	Improves insulin sensitivity
Nausea/GI side effects	Minimal	Common at titration
Weight loss (average)	~2–4 kg over 12 weeks in Phase II	~14.9% body weight over 68 weeks
Best patient profile	Lean individuals, GLP-1 intolerant, no appetite suppression desired	Higher BMI, significant weight loss goal, metabolic improvement needed
TGA approval	Schedule 4 compounding only	TGA-approved (Wegovy)
Monthly cost AUD	$180–$280	$129–$320

The right patient for AOD-9604:

Already lean (BMI 22–27) wanting to remove stubborn body fat without altering eating patterns
Cannot tolerate GLP-1 side effects (nausea, vomiting, gastroparesis risk)
Does not want appetite suppression — prefers to manage nutrition independently
Seeking a specifically fat-targeted mechanism rather than appetite-mediated weight loss

The right patient for semaglutide:

Higher body weight with meaningful reduction goal (10kg+)
Appetite is the primary driver of excess caloric intake
Prepared to manage GI side effects during titration
Wants the most evidence-robust option

Find a prescriber for AOD-9604 in Australia →

ProtocolHub earns a commission when you visit partner links. This does not affect our recommendations.

How to access AOD-9604 legally in Australia

Telehealth consultation with an AHPRA-registered practitioner ($79–$149, or included in subscription models). The practitioner will review your health history and confirm AOD-9604 is clinically appropriate.
Prescription issued to a licensed Australian compounding pharmacy.
Compounded AOD-9604 prepared and dispatched via cold-chain courier. Standard form: lyophilised (freeze-dried) powder for reconstitution with bacteriostatic water.
Protocol: 300 mcg/day, subcutaneous injection, taken fasted in the morning. 12-week cycle. Some practitioners use an 8-week cycle and assess results.

Timeline from consultation to first dose: typically 5–10 business days.

What does AOD-9604 cost in Australia?

Cost component	Amount (AUD)
Initial consultation	$79–$149 (one-off)
AOD-9604 (300 mcg/day, 4-week supply)	$180–$280/month
Ongoing prescription renewal	$49–$99/consultation

No pathology is strictly required before starting AOD-9604 (unlike GLP-1 agents which warrant baseline glucose and HbA1c). However, a body composition baseline — DEXA scan or at minimum waist circumference measurements — gives you a meaningful metric for the 12-week cycle.

Can you stack AOD-9604 with semaglutide?

Yes — the mechanisms are complementary, not overlapping. AOD-9604 acts directly on fat cells via lipolysis. Semaglutide acts via appetite suppression and metabolic improvement. Some Australian practitioners use this combination for patients who have achieved good appetite control on semaglutide but have residual stubborn fat — adding AOD-9604 to address the fat-cell side of the equation.

Discuss this combination explicitly with your prescribing practitioner — both are Schedule 4 and require active management.

Risks and what to watch for

AOD-9604 has a favourable safety profile across its human trial programme. Adverse effects reported in trials:

Headache — mild, typically resolving within the first week
Flushing at the injection site — common, not concerning
Mild nausea — rare; more common at higher doses

What AOD-9604 does NOT do (confirmed in trials): does not raise IGF-1, does not affect blood sugar, does not affect bone density markers in the trial duration studied. No serious adverse events were reported in the Phase III programme.

Long-term safety data beyond the trial durations does not exist for AOD-9604, as with most compounded peptides. The 12-week cycle approach is the current clinical standard in Australia.

ProtocolHub provides educational information only. All peptide therapies require consultation with an AHPRA-registered medical practitioner. This does not constitute medical advice.

AOD-9604: The Fat-Burning Peptide Developed in Melbourne That Most Australians Have Never Heard Of